First Identification of Hemolysin (hylA) Gene in Multi Drug Resistant Acinetobacter baumannii Isolated from Clinical Specimens in Iraq
DOI:
https://doi.org/10.46966/msjar.v5i2.195Keywords:
A. baumannii, Gene, Hemolysin ,VirulenceAbstract
Background: Acinetobacter baumannii is an extremely problematic bacterium because of its multidrug resistance and fast resistance development capabilities. A. baumannii is widely recognized as one of the most difficult nosocomial pathogens for treatment and control. . Objective:The current study aimed to molecular detection of hylA gene and other virulence genes. Subjects and methods: A study that was cross-sectional was carried out over the course of a period of 5 months, from September 2023 and ending in January 2024. A total of 65 clinical samples were collected from two prestigious institutions, namely Baghdad Teaching Hospital and Al-Sadder Medical City, which are situated in the provinces of Baghdad and Najaf, respectively. In order to guarantee that the diagnosis is accurate, the isolates were subjected to a comprehensive processing procedure that included morphological approaches, biochemical testing, and Vitek2 systems. The susceptibility of antibiotics was evaluated for 22 different antibiotics from 9 antimicrobial categories. Using the disk diffusion method and Colistin Broth Disk Elusion Method used for colistin antibiotic .Monoplex and multiplex conventional PCR analysis used to identify specific virulence genes. Results: The investigation involved the examination of 65 specimens obtained from patients ,which included of sputum 31(47.6%), burn exudate 11(16.9%), wound abscesses 8(12.3%) and blood 7(10.7%), buccal swab 4(6.1%), urine 3(4.6%) , pus 1(1.5%) from the total .The majority of the specimens were collected from hospitalized patients 55 (84.6%) ,while there10 (15.3% ) indicating a substantial contrast in comparison to outpatients . PCR amplification revealed the following genes bla OXA-51 52(80%) ,Omp-A 47(90%) and Bap 19 (37%), FimH 13(25%), FimA(0%) , epsA 19(37%), ptk 11 (21.1%), cnf1 19(37%) , hylA 21(40%) . The rates of resistance were as follows: Ampicillin and Pipracillin(100%),Ampicillin-sulbactam (95%) ,Pipracillin-tazobactam (91%) ,Ticarcillinclavulanicacid (92%), Ceftazidime(95%), Cefotaxime, Ceftriaxone and Cefepime (100%), Imipenem (98%), Meropenem (92%). Amikacin (98%), Gentamicin (91%), Tobramycin (77%), Netilmicin (55%), Doxycycline (40%),Minocycline (20%), Ciprofloxacin(94%), Levofloxacin (92%), Gatifloxacin (28%), Trimethoprim/sulfamethoxazole (92%), Colistin (71%). Conclusions: A higher percentage of A.baumannii isolated from sputum samples. High rates of biofilm formation genes (Omp-A and Bap), Toxin production gene(cnf1)followed by capsular polysaccharide genes (EpsA, ptk), Tissue destruction genes (PlcH, PlcN), Adherence genes (FimH) and FimA was not detected.First reporet of hemolysin gene (hylA) in Iraq.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Bushra Ghanem Abdulsadah, Zainab Jaber Hadi
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
